GB Sciences Inc. (OTCMKTS:GBLX) has filed a provisional patent application for the use of its proprietary cannabinoid containing complex mixtures (CCM) for chronic inflammation treatment. Currently, chronic inflammation represents a substantial global economic and health burden, with more than $130 billion spent per year.
GBS conducted a study in the modulation of inflammatory processes
The patent assigned to GBS Global Biopharma Inc. is based on data from a two-year trial on the use of cannabis-derived compounds for modulation of inflammatory processes within human immune cells. Dr. Norbert Kaminski conducted the study at Michigan State University for GBS. The company’s CCCM is designed to minimize chronic inflammation by targeting immune cells and the pro-inflammatory processes contributing to chronic inflammation pathology. Most importantly, GBS’s interest is the development of therapeutics for chronic neuroinflammation patients. There is growing evidence suggesting that the brain’s pro-inflammatory process results in Alzheimer’s, Parkinson’s disease, and HIV-Associated Neurocognitive disorder (HAND) pathologies.
Michigan State University carried human primary blood cell screens, which are state-of-the-science models for evaluating the impact of the compounds on the human immune system. This allows assessment of GB Sciences’ neuroprotective compounds’ as a potential anti-inflammatory treatment.
Cannabis-based compounds can reduce pro-inflammatory processes
Kaminski is a director of the Institute for Integrative Toxicology and Director of the Center for Research on Ingredient Safety at the MSU. He said that the NIH funded research showed a correlation between cannabis uses and decrease in the number of circulating activated monocytes in patients with HIV/AID that have used cannabis compared to those that didn’t. The activated monocytes are often linked with HIV-Associated Neurocognitive Disorder, and they play a vital role in Alzheimer’s and Parkinson’s diseases. According to the study, some cannabis-based compounds have the potential of reducing pro-inflammatory processes.
GB Sciences and GBS Global Biopharma’s Chief Science Officer and Director, Andreas Small-Howard, said that they are looking forward to advancing the studies with Kaminski to bolster the development of novel therapies for the treatment of chronic inflammation. Small-Howard added that the company had used its novel drug discovery platform in addressing around 50 different medical disorders.